Sunday, September 7, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

N-Able Maintains Analyst Confidence Despite Executive Share Sale

Robert Sasse by Robert Sasse
September 7, 2025
in Analysis, Insider Trading, Tech & Software
0
N-Able Stock
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

Market experts continue to endorse N-Able shares with a “Moderate Buy” consensus recommendation, even as the company’s Executive Vice President recently divested a substantial portion of his holdings. This divergence between insider action and analyst outlook presents investors with a compelling puzzle.

Strong Quarterly Performance Underpins Optimism

The bullish stance from Wall Street follows N-Able’s impressive second-quarter results for fiscal 2025. The cloud software specialist reported earnings per share of $0.11, significantly surpassing the $0.09 consensus estimate. Revenue reached $131.25 million, exceeding projections and demonstrating robust year-over-year growth of 9.9 percent.

Five equity researchers covering the company maintain positive ratings, with their collective price target of $9.31 suggesting approximately 18 percent upside from current trading levels. Individual forecasts range from $8.50 to $10.00 per share.

Insider Transaction and Revised Estimates

Despite this optimism, investors noted a notable insider transaction in mid-August. Michael I. Adler, an executive vice president at the company, sold shares valued at nearly $245,000. Such disposals by senior management often attract scrutiny as potential signals about a company’s prospects.

Should investors sell immediately? Or is it worth buying N-Able?

Additionally, analysts have slightly tempered their full-year expectations over the past month. The consensus EPS estimate for fiscal 2025 has been adjusted downward from $0.15 to $0.14.

Strategic Expansion and Maintained Guidance

N-Able continues to execute its growth strategy, particularly in the cybersecurity domain. The November 2024 acquisition of Adlumin enhanced its offerings with cloud-native XDR and MDR solutions. This strategic move is anticipated to contribute to annual recurring revenue (ARR) and cash flow growth by the fourth quarter of 2025.

Management has reaffirmed its full-year 2025 outlook, projecting revenue between $500 million and $503 million. This would represent growth of 7 to 8 percent compared to the previous year.

Upcoming Catalyst and Market Watch

The investment community now turns its attention to the upcoming Q3 2025 earnings release scheduled for November 6. This report will provide crucial insight into whether the analysts’ confidence is well-founded or if the insider’s decision to reduce exposure might indicate challenges ahead. The market will be watching closely to see which perspective proves accurate.

Ad

N-Able Stock: Buy or Sell?! New N-Able Analysis from September 7 delivers the answer:

The latest N-Able figures speak for themselves: Urgent action needed for N-Able investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from September 7.

N-Able: Buy or sell? Read more here...

Tags: N-Able
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

Palantir Stock
AI & Quantum Computing

Palantir Leadership Offloads Shares: A Signal to Investors?

September 7, 2025
Edwards Lifesciences Stock
Analysis

Edwards Lifesciences: A Study in Market Contradictions

September 7, 2025
AMD Stock
AI & Quantum Computing

AMD Shares Face Volatility as AI Strategy Comes Under Scrutiny

September 7, 2025
Next Post
Nurix Therapeutics Inc Stock

Nurix Therapeutics Stock Surges on Renewed Investor Confidence

PayPal Stock

Venmo Emerges as PayPal's Unexpected Growth Engine

Micron Stock

Micron Stock Surges to Record High on Strong AI Demand

Recommended

Vivids Stock

Vivid Seats Shares Plunge Amidst Bleak Quarterly Results

3 days ago
Footwear Industry Stock Market Today (1)

Analyst Bullish on Skechers USA with Increased Price Target

2 years ago
Snowflake Stock

Snowflake Stock Soars as AI Demand Fuels Record Performance

1 week ago
Franklin FTSE India ETF Stock

India’s Stock Market Navigates Crosscurrents as FLIN ETF Faces Challenges

2 weeks ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

AAPL Adobe Alibaba Alphabet AMD AMZN Apple ASML BA Broadcom C Coinbase COST CRWD DIS Eli Lilly Fiserv IBM Intel Kraft Heinz Lockheed Marvell Technology META Micron Microsoft MP Materials MSFT NIO Nvidia Opendoor Oracle Palantir PayPal Pepsi PLTR Realty Income Red Cat Robinhood Rocket Lab USA SMCI Strategy Tesla TSLA Unitedhealth Viking Therapeutics
No Result
View All Result

Highlights

Northwest Biotherapeutics Shares Extend Losses to Fourth Consecutive Session

Origin Materials Faces Critical Juncture Amid Production Delays and Slashed Forecasts

Duke Energy Navigates Financial Pressures Through Strategic Divestments

Halozyme Therapeutics: A Biotech Powerhouse Fueled by Record Royalties

RingCentral Stock: A Tale of Strong Fundamentals and Market Uncertainty

Powering Progress: Ameren’s Dual Strategy for Growth and Sustainability

Trending

Palantir Stock
AI & Quantum Computing

Palantir Leadership Offloads Shares: A Signal to Investors?

by Robert Sasse
September 7, 2025
0

Significant stock sales by Palantir Technologies Inc.'s top executives are delivering a concerning message to the market....

Edwards Lifesciences Stock

Edwards Lifesciences: A Study in Market Contradictions

September 7, 2025
AMD Stock

AMD Shares Face Volatility as AI Strategy Comes Under Scrutiny

September 7, 2025
Northwest Biotherapeutics Stock

Northwest Biotherapeutics Shares Extend Losses to Fourth Consecutive Session

September 7, 2025
Origin Materials Stock

Origin Materials Faces Critical Juncture Amid Production Delays and Slashed Forecasts

September 7, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Recent News

  • Palantir Leadership Offloads Shares: A Signal to Investors? September 7, 2025
  • Edwards Lifesciences: A Study in Market Contradictions September 7, 2025
  • AMD Shares Face Volatility as AI Strategy Comes Under Scrutiny September 7, 2025

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

© 2024 Stocks Today

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com